Used in immunotherapy for cancer treatment by blocking the PD-1 receptor on T-cells, thereby enhancing the immune system’s ability to detect and destroy tumor cells. This antibody helps overcome immune evasion mechanisms used by cancer cells, particularly in solid tumors such as melanoma, non-small cell lung cancer, and renal cell carcinoma. It is employed in research and development of therapeutic antibodies and serves as a reference in preclinical and clinical studies evaluating PD-1 inhibitors. Its use supports the optimization of dosing, efficacy, and safety profiles in immuno-oncology drug development.